Application Number: 10-2021-0006947
Title of Invention: Pharmaceutical composition for treating TRPV1 activation-mediated diseases
With the approval of this domestic patent, RudaCure Inc. has taken one step closer to commercializing RCI002 for various pain conditions.
The company plans to continue expanding its patent portfolio in line with its patent strategy as it secures additional pipelines in the future.